FDA Letter API

Quicksilver Scientific, Inc.

Letter data

Company
Quicksilver Scientific, Inc.
Recipient
Christopher W. Shade, PhD | Quicksilver Scientific, Inc. | 1960 Cherry Street | Louisville | , | CO | 80027 | United States | chris.shade@quicksilverscientific.com
Issue date
2024-09-30
Posted date
Not available
FDA office
Office of Human and Animal Food Operations Division West 4
Subject
Not available
Product
Dietary Supplements
CMS ID
612476
Reference number
Not available
FEI
Not available
Inspection dates
Not available

Normalized citations

21 CFR: None found

21 U.S.C.: None found

Related FDA links

No related FDA letter link is present in the source index.

Full source text

CLOSEOUT LETTER Quicksilver Scientific, Inc. MARCS-CMS 612476 — September 30, 2024 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: Via Email Product: Dietary Supplements Recipient: Recipient Name Christopher W. Shade, PhD Quicksilver Scientific, Inc. 1960 Cherry Street Louisville , CO 80027 United States chris.shade@quicksilverscientific.com Issuing Office: Office of Human and Animal Food Operations Division West 4 United States Secondary Issuing Offices United States Dear Dr. Shade: The Food and Drug Administration has completed an evaluation of your firm’s corrective actions in response to our Warning Letter CMS Case # 612476, dated October 13, 2021. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections. This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means. Sincerely, /S/ E. Mark Harris Program Division Director Office of Human and Animal Food Operations – West Division 4 Content current as of: 10/03/2024 Regulated Product(s) Dietary Supplements